Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C
Bo Feng,Jia Shang,Shuhuan Wu,Hong Chen,Ying Han,Yueqi Li,Dazhi Zhang,Longfeng Zhao,Shaofeng Wei,Qing Mao,Zhibiao Yin,Tao Han,Maorong Wang,Shijun Chen,Jun Li,Qing Xie,Zhen Zhen,Zhiliang Gao,Yuexin Zhang,Guozhong Gong,Dongliang Yang,Chen Pan,Jifang Sheng,Hong Tang,Qin Ning,Guangfeng Shi,Junqi Niu,Guanghan Luo,Yongtao Sun,Hong You,Guiqiang Wang,Lunli Zhang,Jie Peng,Qin Zhang,Jiajun Liu,Chengwei Chen,Xinyue Chen,Wei Zhao,Runhua Wang,Li Sun,Lai Wei
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2017.03.006
2017-01-01
Abstract:Objective To investigate the efficacy and safety of the new investigational drug pegylated interferon α-2b (Peg-IFN-α-2b) (Y shape,40 kD) injection (180 μg/week) combined with ribavirin in the treatment of patients with genotype 1/6 chronic hepatitis C (CHC),with standard-dose Peg-IFN-α-2a combined with ribavirin as a positive control.Methods A multicenter,randomized,open-label,and positive-controlled phase Ⅲ clinical trial was performed.Eligible patients with genotype 1/6 CHC were screened out and randomly divided into Peg-IFN-α-2b(Y shape,40kD) group and Peg-IFN-α-2a group at a ratio of 2∶1.The patients in both groups were given oral ribavirin for 48 weeks in addition and then followed up for 24 weeks after drug withdrawal.Abbott Real Time HCV Genotype Ⅱ was used to determine HCV genotype,and Cobas TaqMan quantitative real-time PCR was used to measure HCV RNA level at 0,4,12,24,48,and 72 weeks.Adverse events were recorded in detail.The primary efficacy endpoint was sustained virological response (SVR),and a non-inferiority test was also performed.Results A total of 561 patients with genotype 1/6 CHC were enrolled,among whom 529 received treatment;90.9％ of these patients had genotype 1 CHC.The data of the full analysis set showed that SVR rate was 69.80％ (95％ CI 65.00％-74.60％) in the trial group and 74.16％ (95％ CI 67.73％-80.59％) in the control group (P =0.297 0).The data of the per protocol set (PPS) showed that SVR rate was 80.63％ (95％ CI76.04％-85.23％) in the trial group and 81.33％ (95％ CI 75.10％-87.57％)in the control group (P =0.849 8),and the 95％ CI of rate difference conformed to the non-inferiority standard.The analysis of the PPS population showed that of all subjects,47.9％ achieved rapid virologic response,with a positive predictive value of 93.8％.The incidence rate of adverse events was 96.30％ in the trial group and 94.94％ in the control group,and the incidence rate of serious adverse events was 5.13％ in the trail group and 5.06％ in the control group.Conclusion In the regimen of Peg-IFN-α combined with ribavirin for the treatment of genotype 1/6 CHC,the new investigational drug Peg-IFN-α-2b(Y shape,40 kD) has comparable clinical effect and safety to the control drug Peg-IFN-α-2a.